December 2021

Issue Highlights

- Newly Activated Studies
- The Cancer Letter
- Accruals & Biospecimens
- CCDR Accruals
- Diving into Disparities
- Smiling Faces

Newly Activated Studies

These studies have recently activated. More information can be found on CTSU.

- NRG BN011: A Phase III Trial of Lomustine-Temozolomide Combination Therapy Versus Standard Temozolomide in Patients with Methylated MGMT Promoter Glioblastoma
- A211901: Reaching Rural Cancer Survivors Who Smoke Using Text-Based Cessation Interventions
- A032002: Phase II Randomized Trial of Atezolizumab Versus Atezolizumab and Radiation Therapy for Platinum Ineligible/Refractory Metastatic Urothelial Cancer (ART)
- S2012: Randomized Phase II/III Trial of First Line Platinum/Etoposide with or Without Atezolizumab (NSC#783608) in Patients with Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
NRG-GU011: A Phase II Double-Blinded, Placebo-Controlled Trial of PROstate OligoMETastatic RadiotHERapy with or Without ANdrogen Deprivation Therapy in Oligometastatic Prostate Cancer (NRG Promethean)
Under-Represented Populations

GY3 November 2021 Accruals By Affiliate Site

NCI Assigned Performance Tracking
GY3 November YTD 2021

Under-Represented Populations
The National Cancer Institute (NCI) Division of Cancer Control and Population Sciences (DCCPS) will host a series of webinars to increase familiarity with purpose of and key

Underrepresented Populations

<table>
<thead>
<tr>
<th>All Accruals</th>
<th>Aug 2021</th>
<th>Sept 2021</th>
<th>Oct 2021</th>
<th>Nov 2021</th>
<th>Goal GY3</th>
<th>Status GY3</th>
</tr>
</thead>
<tbody>
<tr>
<td>AYA (15-39 yrs.)</td>
<td>2</td>
<td>1</td>
<td>2</td>
<td>1</td>
<td>4%</td>
<td>9.96%</td>
</tr>
<tr>
<td>Older Adults (&gt;65 yrs.)</td>
<td>24</td>
<td>16</td>
<td>13</td>
<td>22</td>
<td>55%</td>
<td>34%</td>
</tr>
<tr>
<td>African American</td>
<td>12</td>
<td>15</td>
<td>12</td>
<td>7</td>
<td>17.6%</td>
<td>21%</td>
</tr>
<tr>
<td>Other Minorities</td>
<td>1</td>
<td>2</td>
<td>0</td>
<td>0</td>
<td>0.4%</td>
<td>1.4%</td>
</tr>
<tr>
<td>Hispanic</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>1%</td>
<td>1.4%</td>
</tr>
<tr>
<td>Rural</td>
<td>23</td>
<td>26</td>
<td>19</td>
<td>11</td>
<td>35%</td>
<td>36%</td>
</tr>
</tbody>
</table>

CCDR Registrations GY3 (Aug - November, 2021) = 10

<table>
<thead>
<tr>
<th>Protocol</th>
<th>SMC</th>
<th>BSSF</th>
<th>AnMed</th>
</tr>
</thead>
<tbody>
<tr>
<td>NRG-CC007CD</td>
<td>0</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>WF-30917CD</td>
<td>2</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>WF-1805CD</td>
<td>1</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>WF-1805CD (NON-PATIENT)</td>
<td>0</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>URCC-1804CD (Sites registered)</td>
<td>0</td>
<td>0</td>
<td>N/A</td>
</tr>
<tr>
<td>URCC-18110CD (NON-PATIENT)</td>
<td>0</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>URCC-18110CD (PATIENT)</td>
<td>2</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>URCC-18110CD (CAREGIVER)</td>
<td>2</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Site Total</td>
<td>7</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>UC-NCORP Total</td>
<td>10</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
methodological considerations in cluster randomized trials, share experiences about conducting cluster randomized trials in NCORP CCDR (10 protocols to date), and discuss strategies for the design and conduct of future cluster randomized trials that balance scientific rigor and feasibility.

- Making the Numbers Work: Design Considerations in NCORP CCDR Trials
- January 26, 2022 | 4:00 – 5:30 p.m.

All About AYA

AYA Accrual GY3 Aug - Nov 2021 - 6

Diving into Disparities

Check out this great article on ACCURE and how the group is taking actions to tackle cancer disparities.

Click Here

Smiling Faces

Great job Bon Secours for being on the ball and accruing 2 patients to their
newly activated protocol EAQ202! BSSF is one of only 6 sites in the nation who have accrued to this study!
Way to Go AnMed for completing NRG-CC007CD, 25 patient goal!
Keep up the great work everyone!

Do you have any staff you would like highlighted in The Connector? Please submit it by the 15th of the month to Alaina: akenney@srhs.com

Connect with us on LinkedIn! @UpstateCarolinaNCORP

Administrator
Kamara Mertz-Rivera, MA, CCRC
Email: UpstateNCORP@srhs.com
Phone: 864-560-6104

Regulatory
Laura Bailey, BS, CCRP
Email: UpstateNCORPRegulatory@srhs.com
Phone: 864-560-6954

Finance
Alex Akkary, MBA
Email: UpstateNCORPFinance@srhs.com
Phone: 864-560-6967

Quality Assurance
Kelsey Bridges, MSHS, ACRP-CP
Email: UpstateNCORPQA@srhs.com
Phone: 864-560-1961

CCDR Coordinator
Melyssa Foust, MSN, RN, OCN
Email: UpstateNCORPCCDR@srhs.com
Phone: 864-560-1035

AYA Coordinator
Heather Schwartz, MPH, HTL
Email: heather_schwartz@bshsi.org

2759 Hwy 14 South • Greer • SC • 29651